Blinatumomab Maintenance After Allo-HSCT
NCT06438796
·
clinicaltrials.gov ↗
PHASE2
Phase
NOT_YET_RECRUITING
Status
59
Enrollment
OTHER
Sponsor class
Conditions
High Risk Acute Lymphoblastic Leukemia
Interventions
DRUG:
Blinatumomab
Sponsor
Ruijin Hospital